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Chocolate as a food matrix reduces the bioavailability of 7 
galloylated catechins from green tea in healthy women 8 
Rie Mukai*a,b, Takashi Fukuda a, Asami Ohnishi a, Takeshi Nikawa c, Mutsuki Furusawaa and 9 
Junji Teraoa 10 
In this study, we evaluated the food matrix effects of chocolate on absorption of green tea catechins (GTCs), (−)-11 
epicatechin (EC), (−)-epigallocatechin (EGC), (−)-epicatechin gallate (ECg), and (−)-epigallocatechin gallate (EGCg), 12 
in five healthy 22-year-old women. In the single-intake experiment, the plasma concentrations of ECg (P < 0.05, at 13 
1.5 h) and EGCg (P < 0.05, at 6 h) but not those of EC and EGC were reduced by the chocolate matrix. Regardless 14 
of the chocolate matrix, ECg and EGCg were mainly present as their aglycones in the plasma, whereas EGC and EC 15 
were found mostly as conjugated metabolites. After daily intake of GTCs mixed with chocolate for 14 days followed 16 
by overnight fasting, ECg but not EGCg was detected in the plasma. To compare the plasma profiles of ECg and17 
EGCg, a mixture containing approximately equal amounts of ECg and EGCg was administered to nine rats for 1418 
days. Following treatment and overnight food deprivation, the plasma content of ECg was higher than that of19 
EGCg. After a single injection of the same mixture in seven rats, ECg levels were higher than those of EGCg, and a 20 
greater amount of conjugated metabolites of ECg than those of EGCg was detected in the plasma 10 h after21 
administration. In conclusion, the chocolate matrix affects the plasma profiles of GTCs, particularly ECg. ECg22 
appears to persist in the plasma for a longer period, regardless of the chocolate matrix.23 
Introduction 24 
Catechins in green tea exert anti-inflammatory and anti-25 
obesity effects in humans through their antioxidative 26 
action.1-3 The four major green tea catechins (GTCs) are (−)-27 
epicatechin (EC), (−)-epigallocatechin (EGC), (−)-28 
epicatechin gallate (ECg), and (−)-epigallocatechin gallate 29 
(EGCg) (Fig. 1).4 EGCg, which has the most potent 30 
antioxidant potential, possesses numerous health-31 
promoting properties, such as anti-obesity and anti-32 
cardiovascular-disease1, 3 properties, whereas EC and ECg 33 
exert cardioprotective effects.5-8 34 
The bioavailability of GTCs has been demonstrated in 35 
animal and human studies. After being consumed, GTCs 36 
undergo conjugation or methylation in the intestinal 37 
mucosa and liver,9 with their plasma concentrations 38 
peaking within 90 to 180 min. These metabolites pass into 39 
enterohepatic circulation.10, 11 In addition, GTCs reaching 40 
the large intestine are converted into several species of 41 
organic acids by the gut microflora.11 Pharmacokinetic 42 
studies have found that all catechin components are 43 
cleared from the plasma within 24 h and excreted in the 44 
urine within 48 h of consumption.10, 12 Thus, to experience 45 
the beneficial effects of GTCs, it may be necessary to ingest 46 
them regularly. GTCs are mainly ingested by beverages, but 47 
since the stability of GTCs in liquids is reported as low,13 we 48 
considered using solid foods as the food matrix to GTCs. If 49 
it could be ingested GTCs in food other than beverages, 50 
more people can achieve the health benefits of catechins. 51 
For example, it can be supplied for elderly people with 52 
chronic disease at risk of aspiration, and astronauts who 53 
exposing oxidative stress during space flight because of the 54 
portability.14 Chocolate is eaten all over the world, and 55 
since it can suppress the bitterness of catechins, it was 56 
applied as the food matrix in the current study. In addition, 57 
since chocolate contains EC oligomers (procyanidins) that 58 
would affect the bioavailability of GTEs, in this study, we 59 
examined the effect of cacao polyphenols on the 60 
bioavailability of GTCs. 61 
We aimed to investigate the impact of chocolate as a food 62 
matrix on the bioavailability of GTCs; in particular, plasma 63 
profiles reflecting conjugation metabolism and dynamic 64 
changes to GTC plasma concentrations were assessed. 65 
Experimental 66 
Materials 67 
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The GTC mixture was obtained from Taiyo Kagaku 68 
(Sunphenon BG-5 for humans and Sunphenon 20 ECg-OP 69 
for rats; Mie, Japan). The weight percentages of each 70 
catechin in the mixture were as follows: Sunphenon BG-5 71 
(quantified  by our laboratory): EC (9.1%), EGC (28.7%), ECg 72 
(2.9%), EGCg (27.0%), and other catechins (5.2%); 73 
Sunphenon 20ECg-OP (quantified by Taiyo Kagaku): EC 74 
(3.6%), EGC (2.3%), ECg (33.8%), EGCg (27.9%), and other 75 
catechins (4.4%). Milk chocolate and milk chocolate-mixed 76 
Sunphenon BG-5 were provided by LOTTE Co. Ltd. (Tokyo, 77 
Japan). The milk chocolate contained 7.6% protein, 33.8% 78 
fat, and 56% carbohydrate. Ethyl gallate and ascorbic acid 79 
were purchased from Wako Chemicals (Osaka, Japan). β-80 
Glucuronidase, EC, and EGCg were obtained from Sigma (St. 81 
Louis, MO), while ECg and EGC were purchased from Kurita 82 
Kogyo Co. (Tokyo, Japan). All other reagents used in the 83 
study were commercially available and of analytical and 84 
high-performance liquid chromatography (HPLC) grade. 85 
 86 
Human study 87 
This study was conducted according to the guidelines of 88 
the Declaration of Helsinki, and all procedures involving 89 
human subjects were approved by the ethical committee 90 
of Tokushima University (Tokushima, Japan; approval 91 
number 346). All subjects gave their informed verbal 92 
consent for inclusion before they participated in the study.  93 
The single-intake study (Exp. I) and continuous-intake 94 
study (Ex. II) were carried out separately. 95 
Exp.I Healthy female volunteers aged 22 years (BMI = 16.2-96 
20.2) were enrolled (n = 5). Three kinds of test meals were 97 
prepared: 375 mg of Sunphenon BG-5 (BG-5) in 200 mL of 98 
water, 20 g of chocolate (Cho), or 20 g of chocolate with 99 
375 mg BG-5 (Cho + BG-5). The catechin composition of 100 
each test meal is listed in Table 1. All subjects took the 101 
same test meal at the same time. The experimental order 102 
was Cho + BG-5, Cho, and BG-5. The washout period 103 
between the test meal was 7-8 weeks. The protocol of Exp. 104 
I was described in a previous report.15  Briefly, all subjects 105 
were asked to avoid catechin-rich foods and drinks for one 106 
day before the experiment. After an overnight food fast, 107 
blood samples were collected into heparinised tubes just 108 
before test meal intake, then 1.5 and 6 h after 109 
consumption. 110 
Exp. II Healthy female volunteers aged 22 years (BMI = 111 
16.2-21.6) were enrolled (n = 5). Four of them were the 112 
same women as Exp.I, one of them was changed to another 113 
woman (There was no health problem, but personal 114 
reason). The study subjects ingested test meal once a day 115 
at 12:00 pm for 14 days. All subjects took the same test 116 
meal at the same time. The experimental order was Cho + 117 
BG-5, and Cho. The washout period between the test meal 118 
was 5 weeks. All subjects were instructed to consume their 119 
usual diet, except for catechin-rich foods and drinks, during 120 
the experimental period. Fasting blood samples were 121 
collected into heparinised tubes at day 0 (just before the 122 
first intake), 15 (24 h after final intake), and 22 (after a 123 
seven-day washout period) after overnight fasting. To 124 
control the baseline plasma levels of catechins, the same 125 
feeding restrictions as in Exp. I was applied the day before 126 
each blood collection.  127 
The plasma was separated by centrifugation at 9,000 × g 128 
for 10 min at 4°C, then stored at -30°C until analysis. 129 
 130 
Animal experiments 131 
All animal experiments were performed in accordance with 132 
the guidelines for the care and use of laboratory animals 133 
set by Tokushima University, Japan (approval number 134 
12144). The protocol was approved by the Committee on 135 
Animal Experiments of Tokushima University. All surgeries 136 
were performed under anaesthesia, and efforts were 137 
made to minimise animal suffering. 138 
Male Wistar rats (Japan SLC) were housed in a room 139 
maintained at 23 ± 1°C with a 12 h light-dark cycle. The 140 
animals were allowed free access to a commercial diet 141 
(AIN-93M, Oriental Yeast Co., Ltd. Tokyo, Japan) and water. 142 
Before test meal administration, they were deprived of 143 
food for 24 h but had free access to water. Nine rats (three 144 
15-, 19-, and 27-week-old, respectively) were included in 145 
the daily injection study (Exp. III). The catechin composition 146 
of each test substance is listed in Table 2. Sunphenon 20 147 
ECg-OP (ECg-OP) was dissolved in water and administered 148 
to the rats once a day for 14 days through a gastric feeding 149 
tube (100 mg/kg body weight). Blood samples were 150 
collected on day 0 (just before the first dose) and 14, 151 
following 24 h food deprivation. Seven rats (three eight- 152 
and four 19-week-old) were included in the single-injection 153 
study (Exp. IV). ECg-OP was dissolved in water and 154 
administered to the rats via a gastric feeding tube (200 155 
mg/kg body weight). Blood samples were drawn just 156 
before injection, then at 1, 4, 8, 10, 18, and 24 h after 157 
injection. The plasma was separated by centrifugation at 158 
9,000 × g for 10 min at 4°C, then stored at -30°C until 159 
analysis. 160 
 161 
Sample preparation for HPLC analysis 162 
The sample preparation method was described 163 
previously.15 Total plasma concentration of each catechin 164 
(including aglycones and their conjugated metabolites) 165 
was determined using HPLC after deconjugation treatment. 166 
Plasma was incubated with β-glucuronidase (1 U/µl; 167 
Sigma) in 0.1 M sodium acetate buffer (pH 5.0) and 50 mM 168 
ascorbic acid for 30 min. To measure the aglycone 169 
concentration, plasma without deconjugation treatment 170 
was analysed. Ethyl gallate was added to the samples as an 171 
internal standard. The liberated aglycones were extracted 172 
with ethyl acetate (Kanto Chemical Co., Inc., Tokyo, Japan) 173 
and evaporated using a centrifugal evaporator, then 174 
dissolved in the mobile phase (50 mM lithium acetate, 13% 175 
methanol, 2% acetic acid). Finally, the samples were 176 
injected into the HPLC detection system. 177 
 178 
HPLC analysis 179 
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The concentration of catechin in human plasma was 180 
determined using HPLC with an electrochemical detector 181 
at 300 mV application voltage (COULOCHEM III, Esa), 182 
equipped with a TSK-gel ODS-80Ts HPLC column (150 × 4.6 183 
mm; Tosoh, Tokyo, Japan). The mobile phase was 50 mM 184 
lithium acetate, 13% methanol, and 2% acetic acid, and the 185 
flow rate was 0.9 mL/min. 186 
The same detection system, equipped with a Cadenza CD-187 
C18 column (75 × 4.6 mm; Imtakt, Kyoto, Japan) was used 188 
for rat plasma. The mobile phase was 1% acetic acid and 189 
acetonitrile (90/10, v/v) and the flow rate was 1.0 mL/min. 190 
 191 
Statistical analyses 192 
Data are expressed as the mean ± standard error (SE). 193 
Differences between three or more groups were analysed 194 
using one-way analysis of variance with Bonferroni post 195 
hoc test for multiple comparisons, whereas differences 196 
between two groups were assessed using a two-sided 197 
Student’s t-test. Differences with P < 0.05 were considered 198 
statistically significant, and the significance levels quoted 199 
were two-sided. All statistical analyses were performed 200 
using Excel Tokei Ver.7.0 for Windows (ESUMI Co., Ltd., 201 
Tokyo, Japan). 202 
Results and Discussion 203 
 204 
Plasma catechin concentration after a single intake or 205 
continuous intake of GTCs mixed with chocolate  206 
Changes in the plasma concentration of each catechin after 207 
a single test food intake are shown in Fig. 2. Catechins with 208 
a galloyl moiety (i.e., EGCg and ECg) were more poorly 209 
absorbed than those without a galloyl moiety (i.e., EC and 210 
EGC), with ECg displaying the lowest plasma levels of all 211 
measured catechins. At 1.5 h after test food intake, the 212 
plasma concentration of ECg was significantly lower in the 213 
BG-5 + Cho group than in the BG-5 group (P = 0.003) and 214 
remained fairly constant until the 6 h mark. Similarly, the 215 
plasma concentration of EGCg at 1.5 h was lower in women 216 
consuming BG-5 + Cho than in those consuming BG-5 217 
alone; however, the difference was not statistically 218 
significant (P = 0.112). Unlike ECg, the plasma content of 219 
EGCg dropped between 1.5. and 6 h after the test food 220 
intake. Chocolate did not influence the plasma 221 
concentration of EC or EGC.  222 
In the single-intake experiment, the plasma concentrations 223 
of ECg and EGCg were lowered by mixing them with 224 
chocolate. The absorption of GTCs is affected by the food 225 
matrix.16-18 The bioavailability of EGCg and ECg, but not 226 
that of EC and EGC, is reduced by skim milk, caseinase, and 227 
soy protein.16 The proteins contained in these foods are 228 
suggested to impair the absorption of EGCg and ECg. The 229 
chocolate used in this study contained 7.6% protein, which 230 
may have inhibited intestinal absorption of ECg and EGCg. 231 
The fat content of chocolate (33.8% in the current study) 232 
also seems to affect the intestinal absorption of GTCs. The 233 
log P values (a measure of hydrophobicity) of EGC, EC, 234 
EGCg, and ECg were -0.50, +0.11, +0.39, and +1.06, 235 
respectively.19 The gallate moiety on the C ring increases 236 
the hydrophobicity of the molecule. It is assumed that the 237 
higher the hydrophobicity of the catechin, the slower its 238 
release from the chocolate matrix. Thus, EGC and EC, which 239 
are hydrophilic, may be more easily released from the food 240 
matrix and enter the digestive juice more readily than 241 
hydrophobic EGCg and ECg. 242 
EGCg and ECg mostly existed as aglycones in human plasma 243 
(Fig. 3). The ratio of aglycone of EGCg to total EGCg was 244 
significantly lower after BG-5 + Cho consumption than after 245 
BG-5 consumption (P = 0.033). 246 
According to previous reports, GTCs with a galloyl moiety 247 
at the 3-position mostly exist as aglycones in the plasma.20, 248 
21 Our results obtained 1.5 h after test food intake may 249 
reflect conjugation metabolism in enterocytes and 250 
hepatocytes (Fig. 2). Chocolate increased the levels of 251 
conjugation metabolites of EGCg (Fig. 3). To our knowledge, 252 
this is the first report to demonstrate that food 253 
components can enhance the conjugation metabolism of 254 
ingested GTCs. 255 
After 14 days of daily test food intake, the plasma 256 
concentration of ECg was increased in women consuming 257 
BG-5 + Cho, and it was significantly higher than in those 258 
consuming chocolate alone (P = 0.034) (Fig. 4). EC present 259 
in chocolate increased plasma EC levels in the Cho group. 260 
However, since the EC content of BG5 was 10 times higher 261 
than that of chocolate, the plasma EC concentration was 262 
higher in the Cho + BG5 group than in the Cho group on day 263 
15. Chocolate had no effect on the plasma concentration 264 
of EGC. The plasma content of EGCg was markedly lower 265 
than that of ECg, and it did not change significantly during 266 
the study period. Plasma levels of all catechins returned to 267 
baseline after a seven-day washout period (day 22). 268 
The results of our human experiment imply that excessive 269 
accumulation of ECg resulting from daily intake can be 270 
avoided because plasma ECg levels returned to baseline 271 
after a seven-day washout period (day 22). Our data 272 
provide evidence that daily consumption of GTCs is 273 
required to achieve the desired health-promoting effects, 274 
such as anti-atherosclerotic,8 antioxidative,22, 23 and 275 
nephroprotective24 effects. As reported by Kawai et al.8, 276 
ECg was detected in foamy macrophages in human 277 
atherosclerotic aorta by using specific antibodies to ECg, 278 
where it was shown to inhibit the expression of CD36, a 279 
class B scavenger receptor implicated in the development 280 
of atherosclerosis. Maintenance of an appropriate level of 281 
ECg in the blood through daily consumption of GTCs could 282 
facilitate ECg transport to atherosclerotic lesions. 283 
The results of our single-intake experiment in women 284 
showed that 1.5 h after test food consumption, the 285 
maximum plasma levels of ECg and EGCg were lowered by 286 
chocolate, whereas those of EC and EGC were comparable 287 
between the BG-5 and BG-5 + Cho groups. In contrast, after 288 
14 days of daily test food intake, the plasma concentration 289 
of ECg was higher in women ingesting BG-5 + Cho than in 290 
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those consuming BG-5 alone. These data suggest that 291 
chocolate delays intestinal absorption of ECg after a single 292 
intake, without reducing the total amount of absorbed ECg. 293 
Although the plasma content of ECg was much lower than 294 
that of EGCg at 1.5 h after a single BG-5 intake (Fig. 2), after 295 
14 days of daily BG-5 intake followed by an 18 h fast, ECg 296 
concentration exceeded that of EGCg (Fig. 4). These data 297 
suggest that ECg could be a preferred food factor that 298 
exerts beneficial effects on vascular endothelium function 299 
upon daily intake of tea catechins. Previous studies on 300 
catechin bioavailability demonstrated that the clearance of 301 
ingested ECg from plasma is slower than that of EGC and 302 
EGCg.9, 22 In the study by Van Amelsvoort et al., the plasma 303 
concentrations of EGC and EGCg returned to basal levels 304 
within 24 h of test meal ingestion, whereas that of ECg 305 
remained. 22 Therefore, ECg may be eliminated more 306 
slowly and persist in the blood for a longer period than 307 
EGCg.  308 
Approximately 15% of the polyphenols in chocolate are 309 
procyanidins, such as procyanidin B2 [epicatechin-(4β-8)-310 
epicatechin], procyanidin C1 (trimer), and cinnamtannin 311 
A2 (tetramer).25 The chocolate used in our clinical 312 
investigation contained 144 mg polyphenols per 20 g 313 
(determined using the Folin-Ciocalteu method; data not 314 
shown), thus, it was estimated to contain approximately 20 315 
mg procyanidins per 20 g. Among them, procyanidin B2 is 316 
partly absorbed as EC and its conjugated/methylated 317 
metabolites.26, 27 Therefore, EC in the plasma of women 318 
consuming chocolate-mixed BG-5 or chocolate alone may 319 
partly originate from procyanidins, such as procyanidin B2. 320 
However, the impact of procyanidins on the absorption of 321 
monomeric catechins is not yet fully understood. Further 322 
studies are required to clarify the interactions between 323 
catechins and procyanidins, and the effects of procyanidins 324 
on GTC absorption when chocolate is used as the food 325 
matrix.  326 
In these clinical studies, it is necessary to monitor the 327 
ingestion during the clinical test, so we had to employ 328 
students who belonged to the university as volunteers. 329 
This was why only 22 - year - old women were selected as 330 
the study subjects, and it was the limit of this study. 331 
However, the effect of chocolate on the bioavailability of 332 
GTCs was properly analyzed because all subjects ingested 333 
their respective test meals reliably. In the future study, it 334 
will be necessary to employ subjects with different genders, 335 
ages, races, health conditions, and eating habits, and to 336 
increase the number of subjects to clarify the food matrix 337 
effect of chocolate. 338 
Pharmacokinetic properties of ECg and EGCg  339 
The pharmacokinetic properties of ECg and EGCg were 340 
assessed in rats to study how the two catechins 341 
accumulate in the plasma. After 14 days of ECg-OP 342 
ingestion, both ECg and EGCg accumulated in the plasma, 343 
and the level of ECg was significantly higher than that of 344 
EGCg (Fig. 5). These results were in accordance with those 345 
of the human study. 346 
After a single gastric injection of ECg-OP, the maximum 347 
plasma concentration of total ECg (conjugates and 348 
aglycones combined) was higher than that of total EGCg 349 
(Fig. 6). The aglycone data followed the same trend until 8 350 
h after ingestion. The concentration of ECg was 351 
significantly higher than that of EGCg between 4 and 24 h 352 
after injection. From 10 h after injection onwards, the 353 
plasma content of total ECg and total EGCg increased, 354 
whereas that of their respective aglycones decreased over 355 
time.  356 
The plasma concentration of total ECg and EGCg peaked at 357 
1.5 h after test substance injection, before steadily 358 
decreasing until the 4 h mark. Between 4 and 8 h after 359 
ingestion, both ECg and EGCg entered various peripheral 360 
tissues, such as the liver, re-entered the duodenum via 361 
enterohepatic circulation, or were eliminated by the 362 
kidneys. From 10 h after ingestion onwards, the plasma 363 
level of total ECg (aglycone and conjugated metabolites 364 
combined) but not that of the aglycone of ECg increased 365 
again, and its concentration was significantly higher than 366 
that of EGCg. Therefore, most ECg was conjugated 367 
metabolites, which were likely reabsorbed via 368 
enterohepatic circulation and/or re-entered circulation 369 
from peripheral tissues. During the latter process, ECg may 370 
undergo conjugation metabolism several times, and the 371 
metabolite profile of ECg present in blood may become 372 
more complex, according to previous studies.9 In contrast, 373 
the EGCg level did not change appreciably after the 10 h 374 
mark. ECg in the body was responsible for its elevated 375 
plasma levels after 14 days of daily GTC intake in women. 376 
ECg seems to undergo more efficient enterohepatic 377 
recycling than EGCg, which likely underlies its longer 378 
persistence in the plasma during regular intake.In addition, 379 
chocolate may influence the plasma ECg profile of humans. 380 
To avoid stress from blood sampling several times in 381 
humans, rats were applied to a time-course study to 382 
confirm the longer persistence of ECg in the blood. 383 
Comparing the metabolite profile of tea catechins between 384 
rats and humans, glucuronides mainly existed in rat plasma, 385 
however not only glucuronides but also sulfates existed in 386 
human plasma.28, 29 In this study, the conjugated 387 
metabolites were hydrolysed by the deconjugation 388 
reaction, and then the total concentration (subtotal of 389 
aglycone and conjugated metabolites) were mainly 390 
analyzed. Therefore, it was not possible to confirm the 391 
effect of the difference in metabolite profile on the plasma 392 
concentration of each catechin. In the pharmacokinetics 393 
study of tea catechins, common results are known to be 394 
obtained from both rats and humans. For example, in both 395 
cases, the maximum concentration of ingested catechins 396 
appears in 1-2 hours, disappears from the blood in about 397 
24 hours, and most of the gallate-type catechins existed as 398 
aglycones.9, 12, 30, 31 Therefore, the plasma concentration of 399 
each catechin in this study can be extrapolated 400 
pharmacokinetics appropriately.  401 
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Conclusions 402 
This study showed that the absorption of catechins with a 403 
gallate moiety (e.g., ECg and EGCg) is reduced by the 404 
chocolate matrix following a single intake of GTCs in 405 
women. However, daily intake of chocolate-mixed GTCs 406 
increased the plasma concentration of ECg but not of EGCg. 407 
Regardless of the chocolate matrix, ECg persisted for a 408 
longer period in the plasma than EGCg after continuous 409 
GTC intake.  410 
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 575 
Table 1. Catechin composition of the test food used in 576 
human experiments 577 




(−)-Epicatechin (EC) 117 132 14 
(−)-Epicatechin gallate (ECg) 25 25 n.d. 
(−)-Epigallocatechin (EGC) 351 351 n.d. 
(−)-Epigallocatechin gallate (EGCg) 221 221 n.d. 
BG-5, Sunphenon BG-5: tea catechin mix for human 578 
experiments. Cho, chocolate 579 
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 581 
Table 2. Catechin composition of the test substance used in 582 
the rat experiments 583 
 584 
  585 










 (µmol/kg body weight) 
(−)-Epicatechin 
(EC) 12.4 24.8 
(−)-Epicatechin gallate 
(ECg)  76.4 152.8 
(−)-Epigallocatechin 
(EGC) 7.5 15.0 
(−)-Epigallocatechin 
gallate (EGCg) 60.9 121.8 
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Figure legends 586 
 587 
Figure 1. Chemical structures of the catechins assessed in 588 
this study. EC: (−)-Epicatechin; EGC: (−)-Epigallocatechin; 589 
ECg: (−)-Epicatechin gallate; EGCg: (−)-Epigallocatechin 590 
gallate. 591 
 592 
Figure 2. Catechin concentration in human plasma after a 593 
single test food intake. Data are expressed as means ± SE (n 594 
= 5). Different letters were assigned when the P-value was 595 
less than 0.05 between the data at the same time point (one-596 
way analysis of variance with the Bonferroni multiple 597 
comparisons test). EC: (−)-Epicatechin; EGC: (−)-598 
Epigallocatechin; ECg: (−)-Epicatechin gallate; EGCg: (−)-599 
Epigallocatechin gallate. 600 
 601 
Figure 3. Effect of the chocolate food matrix on the ratio of 602 
aglycone to total catechin in the plasma of the study subjects. 603 
The ratio of aglycone to total catechin (aglycones and 604 
conjugated metabolites combined) was calculated 1.5 h 605 
after a single test food intake. Data are expressed as means 606 
± SE (n = 5). Asterisks indicate that the P-value between BG-607 
5 and BG-5 + Cho groups is less than 0.05 (two-sided 608 
Student’s t-test). EC: (−)-Epicatechin; EGC: (−)-609 
Epigallocatechin; ECg: (−)-Epicatechin gallate; EGCg: (−)-610 
Epigallocatechin gallate.  611 
 612 
Figure 4. Catechin concentration in human plasma after daily 613 
intake of test food. Data are expressed as means ± SE (n = 5). 614 
Different letters were assigned when the P-value was less 615 
than 0.05 among the data for different periods in the same 616 
test meal (one-way analysis of variance with the Bonferroni 617 
multiple comparisons test). The upper case letter is for Cho, 618 
and the lower case letter is for BG-5+Cho. Asterisks indicate 619 
that the P-value between Cho and BG-5 + Cho groups is less 620 
than 0.05 (two-sided Student’s t-test). EC: (−)-Epicatechin; 621 
EGC: (−)-Epigallocatechin; ECg: (−)-Epicatechin gallate; EGCg: 622 
(−)-Epigallocatechin gallate. n.d.: not detected. 623 
 624 
Figure 5. Catechin concentration in rat plasma after daily 625 
ingestion of ECg-OP. Data are expressed as means ± SE (n = 626 
9). Asterisks indicate that the P-value between EGCg and ECg 627 
levels on the same day is less than 0.05 (two-sided Student’s 628 
t-test). ECg: (−)-Epicatechin gallate; EGCg: (−)-629 
Epigallocatechin gallate. n.d.: not detected. 630 
 631 
Figure 6. Concentration of EGCg and ECg in rat plasma after 632 
a single injection of ECg-OP. (a) Catechin concentration in 633 
the plasma (with deconjugation); (b) Concentration of the 634 
aglycone form of the catechin in the plasma (without 635 
deconjugation). Data are expressed as means + SE (n = 7). 636 
Asterisks indicate that the P-value between EGCg and ECg 637 
levels at the same time point is less than 0.05 (two-sided 638 
Student’s t-test). ECg: (−)-Epicatechin gallate; EGCg: (−)-639 
Epigallocatechin gallate. 640 
 641 
   642 
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